Disclosures for "Comparison of Therapeutic Efficacy of Gene Therapy for Tuberous Sclerosis Type 2 with Standard of Care Everolimus in Preclinical Model")
-
Dr. Abou Haidar has nothing to disclose.
-
Miss Prabhakar has nothing to disclose.
-
The institution of Dr. CHEAH has received research support from MInistry of Higher Education, MALAYSIA.
-
Dr. Lule has received personal compensation for serving as an employee of Codiak Biosciences.
-
Ms. Beauchamp has nothing to disclose.
-
Dr. Yoshinaga has nothing to disclose.
-
Dr. Geffrey has received personal compensation for serving as an employee of Massachusetts General Hospital.
-
Anat Stemmer-Rachamimov has nothing to disclose.
-
Vijaya Ramesh has nothing to disclose.
-
Dr. Maguire has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Chameleon Biosciences. Dr. Maguire has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sphere Gene Therapeutics. Dr. Maguire has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Skylark Bio. Dr. Maguire has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sphere Gene Therapeutics. Dr. Maguire has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for CLS Therapeutics. Dr. Maguire has received stock or an ownership interest from Chameleon Biosciences. Dr. Maguire has received stock or an ownership interest from Sphere Gene Therapeutics. Dr. Maguire has received stock or an ownership interest from Skylark Bio. Dr. Maguire has received research support from SwanBio. Dr. Maguire has received research support from BridgeBio. Dr. Maguire has received research support from Wayvector Inc. Dr. Maguire has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Breakefield has nothing to disclose.